MedTrace Logo

Effects of Linagliptin on Endothelial Function

NCT02350478 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-05-15

Study results available
· View outcomes & findings →

Summary

This study is planned to evaluate if linagliptin can improve endothelial function in patients with type 2 diabetes mellitus. In addition, the effect of linagliptin on arginine bioavailability ratios and postchallenge glycaemic control will be studied.

Conditions

Interventions

DRUG

Linagliptin

The subject will receive Linagliptin 5mg orally once daily for 12 weeks.

DRUG

Placebo

The subject will receive placebo orally once daily for 12 weeks.

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Harald Sourij, Assoc.-Prof. · Medical University of Graz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2017-01-31
Completion
2017-03-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02350478 on ClinicalTrials.gov